Introduction
IL-10 is a major immunosuppressive cytokine produced by T-cells, B-cells, dendritic cells and monocytes / macrophages (Fiorentino et al., 1989) (de Waal Malefyt et al., 1992) (Chang et al., 2000) . The immunosuppressive activity of IL-10 is highlighted by the findings that IL-10 knock-out mice show spontaneous autoimmune disease and increased resistance to infection (Bettelli et al., 1998) (Dai et al., 1997) .
IL-10 acts by binding to the IL-10R1 / IL-10R2 receptor complex, which recruits the kinases Jak1 and Tyk2 and these then phosphorylate and activate Stat3 and -1 transcription factors (Donnelly et al., 1999) (Williams et al., 2004) . IL-10 can suppress the immune response via this signalling cascade by decreasing cell surface expression of MHC class II and by down-regulating the expression of cytokines like TNF (de Waal Malefyt et al., 1991 ). Stat3 appears to be the dominant factor that mediates IL-10 action but how this leads to down-regulation of genes like TNF is still unknown (Williams et al., 2004) .
Changes in the expression of IL-10 upon activation of leukocytes are mainly transcriptional and several factors have been implicated in its control. For the murine IL-10 gene an important role of Sp1 in regulating the LPS-stimulated promoter activity was reported (Brightbill et al., 2000) . The respective motif is promoter proximal and its mutation reduced both the inducible and the constitutive promoter activity in the murine RAW 264 macrophage cell line (Brightbill et al., 2000) (Tone et al., 2000) . Ma et al. (Ma et al., 2001a ) noted a Sp1 site at -636 bp of the human promoter, which appeared to be responsible for all the inducible activity in monoblastic cells. For the human gene, transactivation by catecholamines appears to require the action of C/EBP (Brenner et al., 2003) and the most important motif TTGCAAAA, which is 44 bp downstream of the TATA box. Furthermore, there is evidence for a role of c-Maf in IL-10 gene expression, but c-Maf may act indirectly by activating other transcription factors (Cao et al., 2002) .
Based on deletion and linker scanning analysis we have identified a Stat motif at -120 that is crucial to gene expression in a human B cell line when stimulated with LPS (Benkhart et al., 2000) . This motif was also shown to be essential together with an upstream IRF site for IFN -induced IL-10 expression (Ziegler-Heitbrock et al., 2003) .
These data are in conflict with earlier findings of Takeda (Takeda et al., 1999) , who found increased IL-10 in Stat3 knock-out animals. The role of Stat3 in IL-10 gene expression was, however, confirmed in other cell lines and in knock-out mice (Herbeuval et al., 2004) (Cheng et al., 2003) (Maritano et al., 2004) . Recently it was shown that SOCS3 deficiency in murine TCR-stimulated T cells led to increased Stat3 activity and IL-10 expression (Kinjyo et al., 2006) . Furthermore, constitutive IL-10 expression in T cell lines can be blocked by depletion of Stat3 by RNA interference (Kasprzycka et al., 2006) . Hence it appears that the Stat-motif in the human IL-10 gene may be a central trans-element in regulation of this gene.
Expression of the IL-10 gene is controlled by interferons, in that IFNα induces IL-10 while IFN can downregulate IL-10 gene expression (Ziegler-Heitbrock et al., 2003) . (Chomarat et al., 1993) . When looking at the molecular mechanism, the induction by IFNα was shown to regulated via a IRF-Stat module in the IL-10 promoter (ZieglerHeitbrock et al., 2003) . For IFN mediated suppression of gene expression various mechanisms have been proposed including suppression of Sp3 (Hughes et al., 2002) or down-regulation of C/EBP (Tengku-Muhammad et al., 2000) . The main transcription factor used by IFN is Stat1 (Schroder et al., 2004) . We have shown earlier that over-expression of Stat1 will counter the activation of the human IL-10 promoter (Ziegler-Heitbrock et al., 2003) . In the present report we demonstrate that IFN -induced Stat1 will compete with and displace Stat3 from the endogenous human IL-10 promoter thus leading to suppression of IL-10 gene expression.
Material and Methods

Cell culture and stimulation
The RPMI 8226.1 B cell line (Ziegler-Heitbrock et al., 1994) was grown in 75 cm 2 tissue culture flasks (Greiner, Gloucestershire, UK) in RPMI 1640 medium (Biochrom KG/seromed ® , Berlin, Germany) supplemented with 200 U/ml penicillin, 200 µg/ml streptomycin (15140-122, Gibco, Paisley, UK), 2 mM L-glutamine (25030-024, Gibco), 10 x non-essential amino acids (K 0293, Biochrom KG), 1 mM oxal-acetate, 1 mM pyruvate and 9 µg/ml insulin (O-5003, Sigma-Aldrich, Dorset, UK). This medium was passed through a Gambro U-2000 ultrafiltration column (Gambro Medizintechnik GmbH, Planegg-Martinsried, Germany) to deplete contaminating LPS, followed by the addition of 10 % v/v low LPS fetal calf serum (Biochrom). Cells were pre-treated with IFN at 1000 U/ml (generously provided by Dr. Wieland Wolf, Rentschler Biotechnologie, Laupheim, Germany) and were stimulated with highly purified LPS from Salmonella minnesota (L-6261, SigmaAldrich) at 100 ng/ml unless stated otherwise.
ELISA for IL-10 protein
ELISA was performed using the human IL-10 ELISA system (BMS215/2, Bender MedSystems, Vienna, Austria) according to the manufacturer's instructions. In brief, cell culture supernatants were added to wells with pre-coated anti-IL-10 antibody and biotin-conjugated anti-IL-10 was added, followed by streptavidin-HRP and substrate.
Readings at 450 nm were transformed into pg/ml with reference to recombinant IL-10 standard titration. 
RT-PCR analysis of gene expression
Transfection of RPMI 8226 with reporter plasmids and luciferase assay
Promoter luciferase reporter plasmids used were a construct containing -1044 bp upstream of the IL-10 transcription start (pIL-10 (-1044).luci), a construct containing -195 bp upstream of the IL-10 transcription start .luci, the same construct with a mutation of the IRF-site .luci) and a construct with a trimer of the -120 Stat-site of the IL-10 promoter (p3xLS4.luci) as described in (Benkhart et al., 2000) and (Ziegler-Heitbrock et al., 2003) .
RPMI 8226.1 cells were transfected according to (Shakhov et al., 1990) . In brief, 10 7 cells in 1 ml RPMI 1640 medium supplemented with 2 mM L-glutamine were admixed with 5 μg reporter gene plasmid and 125 μg/ml DEAE-Dextran (E1210, ProFection, Promega, Southampton, UK). After 90 min at 37 C, we added 100 μl of DMSO (D-5879, Sigma-Aldrich) for 150 sec. Cells were then washed and cultured for 4 days in 6 well plates.
Cells were treated with 1000 U/ml IFN and 100 ng/ml LPS and cell lysates were prepared 6 h after LPS treatment using Luciferase Assay System (E1500, Promega), 
Gelshift analysis
Nuclear extracts were isolated according to the method of Dignam et al. (Dignam et al., 1983) in the presence of a protease inhibitor cocktail (10 μg/ml aprotinin (A-6279, Sigma-Aldrich), 1 mM PMSF (P-7626, Sigma-Aldrich), 40 μg/ml leupeptin-propionyl 
Bioinformatic analysis
Analysis of mouse promoters for the combined STAT3/STAT1 motif as found in the human IL10 promoter was carried out as follows (All tools were used as provided on the GenomatixPortal, Genomatix, Munich unless other wise stated): The human promoter was analyzed for STAT3 and STAT1 motifs using a weight matrix based approach (MatInspector, GEMS launcher release 4.2.2). Results were used to define a promoter model using the FASTM tool (GEMS launcher release 4.2.2). The distance between the two STAT binding sites found in the human IL-10 promoter was 2 and was set to a range of 2 -5 in the model. Recognition of the human IL-10 motif was verified using ModelInspector (GEMS launcher release 4.2.2). Then the promoters of genes identified in the microarray study (29) as significantly downregulated (>3) were analyzed for matches of this model as well as the whole database of mouse promoters (ElDorado, release 4.1).
Statistical analysis
Data were analysed using one-tailed paired Student's T-test. Results were considered significant when *p<0.05.
Results
Effect of IFN on IL-10 mRNA and protein
In order to demonstrate that the effect of IFN on the IL-10 promoter will lead to reduced mRNA synthesis we performed RT-PCR in cells at 6hs post LPS stimulation.
Data in Figure 1 A demonstrate a reduction of IL-10 mRNA by factor 2 when cells were pretreated with IFN for 2hs followed by LPS stimulation for 6 hours. Also, IL-10 protein levels were significantly reduced with IFNγ pre-treatment at 18hs post LPS stimulation (Figure 1 B) .
Effect of IFNγ pre-treatment on IL-10 promoter activity
For the study of the IL-10 promoter activity we transfected RPMI 8226 cells with the pIL-10(-1044).luci plasmid using DEAE Dextran. Cells were then stimulated with Mutation of the IRF-motif did not affect the ability of IFN to suppress the IL-10 promoter activity ( Figure 3B , lane 4) indicating that IFN is not acting via this site.
The role of the Stat-site could not be tested by the mutation approach since mutation would ablate the LPS signal, such that there would be no activity to be suppressed.
We therefore turned to a construct carrying a trimer of the Stat motif from the IL-10 promoter. Using this construct IFN could also suppress the LPS-induced promoter activity albeit to a lesser extent (lane 4, Figure 3C ). These data suggests that the suppressive effect of IFN on the human IL-10 promoter may operate via the Stat site.
Taken together, it appears that the regulation of the IL-10 gene by IFN operates via the -120 Stat site.
Effect of IFN on activation of Stat1 and Stat3
We then analysed the effect of IFN on phosphorylaton and mobilisation of Stat 1 and 
Effect of IFN on binding of Stat1 and Stat3 in the intact nucleus
We then performed ChIP analysis in order to investigate whether the Stat1 When looking at ChIP for Stat1 we observed binding of this transcription factor in IFN but not by LPS treated cells (Fig 6 C, lane 2 and 3 ). When cells were treated with IFN plus LPS then Stat1 binding was increased further (Fig 6C, lane 4) . Again these quantitative PCR analyses are supported by an analysis of the 32 cycle products in a gel (Fig 6 D) . These ChIP analyses suggest that IFN treatment induces Stat1 binding, which displaces LPS induced Stat3 from the IL-10 promoter. suppresses MMP-9 via Stat1 (Ma et al., 2001b ) and this appears to be due to sequestration of CBP/p300 such that this coactivator is not available for transcription of the MMP-9 gene (Ma et al., 2005) .
With respect to IFN induced down-regulation of IL-10 Flores et al have studied suppression of this cytokine in CpG stimulated dendritic cells (Flores et al., 2007) They suggested that Stat1 might be involved but the findings were difficult to interpret because IL-10 levels were decreased in Stat1-/-mice such that there was Our studies have demonstrated that suppression of the LPS-induced -1044 IL-10 promoter activity can be achieved when IFN is added simultaneously with LPS but a clearly stronger effect can be achieved when IFN is added at -2hs (see Figure 2 ).
This finding is surprising given that LPS signalling leads to binding of Stat3 to the promoter only with slow kinetics, while IFN can induce strong Stat1 binding already at 1 h ( Figure 5A ). With this faster kinetics for Stat1 induction an additional preculture time would not appear necessary. Hence at this stage the improved suppression with very early addition of IFN remains unexplained. Although data in Figure 2 suggest that a longer pre-culture period might give an even stronger effect, we have not tested earlier addition of the cytokine since we wanted to focus on direct actions of IFN and avoid indirect, secondary effects.
Suppression by IFN was also seen with a shorter -195 fragment of the IL-10 promoter and this contains Stat3 and IRF sites as previously described (ZieglerHeitbrock et al., 2003) . With IFN acting both via Stat and IRF (Schroder et al., 2004) we have then evaluated the role of these two sites. Here, mutagenesis of the IRF-site did not affect the ability of IFN to suppress IL-10 promotor activity (see Fig 3B) .
Hence, while it was shown that IFN suppresses IL-4 via IRF-1 und -2 (Elser et al., 2002) , this mechanism does not appear to be responsible for the suppression of IL-10.
Mutagenesis of the Stat-site is not informative for the study of IFN suppression of the LPS induction, since with mutation of this site there is no induction by LPS (Benkhart et al., 2000) and hence no activity that can be suppressed. We therefore have taken a reporter gene construct containing a trimer of the Stat-motif. As IFN suppressed LPS-induction of this construct we postulate a crucial role of this site for the inhibitory effects of IFN action.
We, in fact, could show induction of nuclear Stat1 and Tyr701 phosphorylation by IFN , which was more pronounced with the combination of LPS and IFN (Fig.4A) . When performing ChIP for Stat1 we observed robust induction of Stat1 binding in IFN /LPS treated cells (Fig 6B) targeting the same element of the IL-10 promoter.
Based on our studies using nuclear translocation, promoter activity analysis, binding in gelshift and ChIP we propose that IFN induced Stat1 will bind to the Stat-motif in the human IL-10 promoter and will displace Stat3. This concept is in line with our earlier finding, which demonstrated that overexpression of Stat1 will reduce IL-10 promoter activity (Ziegler-Heitbrock et al., 2003) . The Stat1 bound to the site can have no activity or only weak transcriptional activity in order to prevent LPS-induced Stat3 mediated IL-10 gene expression.
The Stat1 competition with Stat3 may operate for many other genes besides IL-10. In earlier studies Ehrt et al (Ehrt et al., 2001) have analysed the transcriptome of murine macrophages in response to IFN . Analysis of these data, kindly provided by Drs.
Ehrt and Nathan, for genes suppressed by IFN revealed 89 of 1299 genes that decreased in expression 3-fold or more. In a bioinformatics search of the promoters of 67 of these 89 genes (annotated genes) for binding motifs similar to the Stat motif in the human IL-10 promoter we found 14 genes to contain such a motif in their promoter. We speculate that these genes (MSR2 GeneID 80891, 2210409B22Rik
GeneID 70174 This mechanism, which operates within hours, may be different from what occurs when cells are primed for 1 or 2 days before adding a stimulus (Hu et al., 2006 ) (Herrero et al., 2003) . When using a system with a 2day priming period then this will alter the entire gene expression program of a cell with many indirect effects (Herrero et al., 2003) . The IFN effect occurring within a few hours as analysed in the present report is likely to be direct and to act via immediate signalling using transcription factors like Stat1. Fig. 1 : IFN inhibits LPS induced IL-10 mRNA and protein expression.
Legends to Figures
RPMI 8226.1 cells were treated for 2 h with IFN at 1000 U/ml previous to stimulation with LPS at 100 ng/ml for 6h (mRNA) or 18 h (supernatant protein).
A: IL-10 mRNA. The mean of 9 experiments ± SD is shown.
B: IL-10 protein. The mean of 6 experiments ± SD is shown. 100% = 31.9 ± 23.7 ng/ml. * = p<0.05 when compared to LPS-stimulated cells. 
